Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial.

Rödel, Claus; Liersch, Torsten; Fietkau, Rainer; Hohenberger, Werner; Graeven, Ullrich; Hothorn, Torsten; Arnold, Dirk; Raab, Hans-Rudolf; Wittekind, Christian; Hess, Clemens F.; Staib, Ludger; Becker, H.; Sauer, Rolf

doi:10.1200/jco.2014.32.15_suppl.3500

Cited by 31 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CAO/ARO/AIO-04, eine randomisierte Phase-III-Studie, untersuchte die Addition von Oxaliplatin zu 5-FU in der neoadjuvanten RChT und in der adjuvanten Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms (cT3-4 oder cN+, 0-12 cm ab ano; [30,31]). Die ersten Daten zu frühen Endpunkten sind 2012 publiziert worden [30] In die PETACC-6-Studie wurden 1094 Patienten mit Tumoren innerhalb der letzten 12 cm des Rektums eingeschlossen, gemessen mit dem starren Endoskop [34].…”

Section: Introductionunclassified

Perioperative (Radio-)Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms

Hofheinz

2015

Onkologe

View full text Add to dashboard Cite

Section: Introductionunclassified

Perioperative (Radio-)Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms

Hofheinz

2015

Onkologe

View full text Add to dashboard Cite

“…Moreover, the CAO/ARO/ A10-04 trial comparing preoperative and postoperative chemotherapy with FOLFOX versus fluorouracil alone also showed similar oncologic outcomes in LARC patients, where the 3-year DFS rate was 71.2 % (95 % CI 67.6-74.9) for the 5-FU/LV group and 75.9 % (95 % CI 72.4-79.5, p = 0.03) for the FOLFOX group. However, since this study enrolled the patients on the basis of the clinical staging before neoadjuvant CRT, patients with ypCR (17 %) and yp I (25 %) were also included in the trial [18,19].…”

Section: Discussionmentioning

confidence: 99%

Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy

Lee

Kang

Chae

et al. 2015

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…Only the CAO/ARO/AIO 04 study showed a significantly better DFS (p = 0.03) [39]. No survival benefit was observed with the addition of Ox in the other 3 trials (ACORD 12/0405, NSABP R-04, and PETACC 6) [40][41][42].…”

Section: Fu-based Crt With the Concomitant Use Of Newly Developed Antmentioning

confidence: 97%

Neoadjuvant treatment for locally advanced rectal cancer: a systematic review

Uehara

Nagino

2015

Surg Today

View full text Add to dashboard Cite

We reviewed the history and the current status of neoadjuvant treatment for locally advanced rectal cancer (LARC) in Western countries and Japan. The introduction of total mesorectal excision (TME) and preoperative radiotherapy (RT) were treatment revolutions that resulted in improved local control after curative resection for rectal cancer. However, local relapses still occur, even in the era of TME, and remain a cause of recurrence worldwide. The high rate of distant metastasis after curative resection remains a problem. Furthermore, the introduction of newly developed cytotoxic agents into the LARC treatment strategy continues to be an ongoing challenge. Shifting part of an adjuvant chemotherapy (CTx) regimen to the preoperative period is a promising strategy. Currently, various novel methods, such as induction CTx, consolidation CTx, concomitant administration with RT, and neoadjuvant CTx without RT, have been attempted worldwide. Although some strategies have shown favorable short-term outcomes, the long-term efficacy of the treatments needs be evaluated. At the same time, we must investigate clinical and/or molecular biomarkers to predict the therapeutic effects of each treatment, which is the fastest route to providing ideal personalized therapy for patients with LARC.

show abstract

Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial.

Cited by 31 publications

References 0 publications

Perioperative (Radio-)Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms

Perioperative (Radio-)Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms

Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy

Neoadjuvant treatment for locally advanced rectal cancer: a systematic review

Contact Info

Product

Resources

About